JUN-28-07: Zelnorm is the second IBS drug to be taken off the market. It was pulled because of an increased risk of heart attack and stroke. [
NEWS: ZELNORM]
JUN-12-07: The Chinese drug watchdog agency warned patients to stop taking
Zelnorm and ordered domestic companies to stop producing and selling the drug. [
FDA NEWS: ZELNORM]
MAY-31-07: Swissmedic, the Swiss medical watchdog, has ordered a market withdrawal for
Zelnorm following the FDA's withdrawal earlier this year. [
FORBES: ZELNORM]
MAY-08-07: Last year, an advertisement for
Zelnorm was honored as one of the best prescription drug ads. That was before it was discovered that Zelnorm was linked to a higher risk of heart attack and stroke. [
TRIBUNE: ZELNORM]
MAY-02-07: Advertising for
Zelnorm may have helped it to become a popular drug, despite its negative side effects and limited effectiveness. [
NEJM: ZELNORM]
APR-03-07: Novartis says it is complying with a request by the FDA that it suspend U.S. sales of
Zelnorm, its irritable bowel syndrome treatment. [
C&EN: ZELNORM HEART ATTACK]
MAR-30-07: The Food and Drug Administration has requested that Novartis Pharmaceuticals Corp. voluntarily discontinue marketing of
Zelnorm (tegaserod) based on the recently identified finding of an
increased risk of serious cardiovascular adverse events associated with use of the drug. Novartis has agreed to voluntarily suspend marketing of the drug in the United States; it is currently marketed in 55 other countries. A review of data from 18,000 patients showed that a statistically significant number of people taking Zelnorm had more heart attacks and strokes. [
BLOOMBERG: ZELNORM] [
FDA: ZELNORM]